T he dissemination of new cardiovascular interventions outside of institutions with clinical trial experience has frequently resulted in significantly worse outcomes. [1] [2] [3] The phenomenon has been most rigorously demonstrated in emerging endovascular technologies, such as carotid stenting and endovascular repair of abdominal aortic aneurysms. 1, 3 Transcatheter aortic valve replacement (TAVR) is a new technology, for which the workup and technical skills required to perform the procedure were not iteratively developed but required practitioners to acquire new interdisciplinary skills. Despite the novel skill set required for TAVR, the results of the clinical trials showed exemplary clinical outcomes in highrisk patients. [4] [5] [6] Given the complexity of TAVR, it is unclear whether hospitals without clinical trial experience could produce similar outcomes.
As part of the recent Food and Drug Administration (FDA) approval of TAVR, a close partnership between the principal professional cardiothoracic surgery and cardiology societies and the Centers for Medicare and Medicaid Services (CMS) established criteria for the certification of hospitals as approved TAVR hospitals. 5, [7] [8] [9] The combination of strict institutional and operator criteria for hospital certification and mandatory participation in a postmarket, clinical surveillance Transcatheter Valve Therapy (TVT) registry were without precedent in the initial approval of a new cardiovascular technology. The effects of the unique policies governing TAVR dissemination on clinical outcomes have yet not been fully evaluated.
Medicare data is an excellent resource to evaluate outcomes in TAVR patients because of the nearly universal Medicare insurance coverage of TAVR recipients. Medicare data includes patients both in and outside of clinical trials as opposed to registry studies with short-term outcomes. Our analysis using Medicare data complements previous TAVR Background-Transcatheter aortic valve replacement (TAVR) was approved by the Food and Drug Administration (FDA) in November 2011 after a collaborative technology development process involving professional medical societies, the medical device industry, and the FDA. After FDA approval, TAVR was adopted by numerous hospitals that had not participated in TAVR clinical trials. It is uncertain if outcomes at these hospitals were comparable with those at clinical trial hospitals. Methods and Results-All patients with Medicare physician claims for TAVR between January 1, 2011, and November 30, 2012, were identified, and postoperative mortality was assessed using Medicare enrollment data. Risk-adjusted mortality was calculated via a multivariable model that adjusted for demographics and comorbidities. We identified 5009 patients who underwent TAVR, with 3617 TAVRs performed at 68 hospitals that had participated in clinical trials and 1392 TAVRs performed at 140 nontrial hospitals. The preoperative characteristics of patients at trial versus nontrial hospitals were similar. There were no significant differences in risk-adjusted 30-day mortality ( 
Methods

Patient Population
This study was approved by the Institutional Review Board of the University of Pennsylvania. Between January 1, 2011, and November, 2012, 5009 Medicare fee-for-service patients undergoing TAVR were identified by the presence of Current Procedural Terminology codes 0256T (Implantation of catheter-delivered prosthetic aortic heart valve; endovascular approach) and 0257T (Implantation of catheter-delivered prosthetic aortic heart valve; open thoracic approach) on physician claims paid by CMS. We linked patient claims data with Medicare enrollment information reported on annual Master Beneficiary Summary Files to obtain dates of death and to determine the Medicare eligibility status. All subjects in the primary sample had at least 30 days of potential follow-up, whereas 90-and 180-day analyses were limited to patients undergoing TAVR before October 1, 2012 (n=4138) and July 1, 2012 (n=3070), respectively, to allow for sufficient follow-up. All patients were linked to data in Medicare denominator files to collect age, race, and sex. Comorbidities with >5% prevalence in the cohort, that is, hypertension, congestive heart failure, peripheral vascular disease, deficiency anemia, chronic pulmonary disease, chronic kidney disease, diabetes mellitus, and liver disease, were identified by applying a modified Elixhauser comorbidity index to International Classification of Diseases, Ninth Revision, diagnosis codes to diagnose conditions present on admission at the index hospitalization for TAVR, or were listed on a Medicare claim in the year preceding the patient's index hospitalization. 10
Trial and Nontrial Institutions
Trial institutions were defined as being listed as part of a Edwards Sapien (NCT00530894) or Medtronic CoreValve (NCT01240902) preapproval clinical trial or having an implant before the approval of TAVR by the Food and Drug Administration (November 2, 2011). Participation in these trials was confirmed by inclusion on the major trial publications and confirmation on clinicaltrials.gov.
WHAT IS KNOWN
• Transcatheter aortic valve replacement (TAVR) effectively treats aortic stenosis in many high risk or otherwise inoperable patients, but TAVR is a new and complex technology that requires new skills to be learned by both interventional cardiologists and cardiac surgeons.
• The approval of TAVR by the Food and Drug Administration and CMS differed from previous cardiovascular interventions and requires joint specialty professional participation in a Heart Team with specific procedural experience requirements for both operators and institutions.
WHAT THE STUDY ADDS
• TAVR technology diffusion is unique among recent, novel cardiovascular interventions in that outcomes were preserved at centers that had no previous experience in preapproval clinical trials.
• TAVR outcomes were also unique in that early institutional experience, and a potential learning curve period were not associated with increased mortality. Data are n (%) unless otherwise specified. Elixhauser comorbidities which were present in <5% of the patient population were excluded. 10 Hospital Trial Participation and TAVR Outcomes
Outcomes
In-hospital complications were identified using diagnosis codes not listed as present on admission at the index hospitalization for TAVR, as well as using all procedure codes occurring during the index hospitalization. Both pre and postprocedure length of stay were calculated using admission, TAVR, and discharge dates as reported on the inpatient Medicare claim. Mortality rates were calculated from duration of survival after the procedure date and include deaths from all causes. Nonmortality outcomes for the 90-day analysis were identified using all diagnosis codes from rehospitalizations occurring within 90 days of the date of surgery. The role of increasing hospital experience on outcomes was evaluated in all hospitals based on surgical AVR volume and in nontrial hospitals comparing their first 10 cases and all subsequent cases. A case volume of 10 was chosen to maximize the number of hospitals where this analysis could be performed because of published outcome differences with increasing institutional experience with new cardiovascular procedures following the first 10 to 30 cases. 11, 12 
Statistical Analysis
Continuous variables were analyzed by t tests, and categorical variables were analyzed using χ 2 and Fisher exact tests. Mann-Whitney tests were used on non-normally distributed continuous variables. Multivariable logistic regression models with generalized estimating equations using an exchangeable correlation structure were used to assess risk factors for 30-and 180-day mortality with a step-wise backwards elimination process using an exclusion criterion of P>0.2.
The variables of sex, age, and trial status were forced into the model. Kaplan-Meier approach was used to compare overall survival between 2 comparison groups. Patients were followed from the date of the procedure until death or the end of study period. Those alive at the end of the study period were censored. All analysis was completed using SAS version 9.3 (SAS Institute Inc, Cary, NC).
Results
Study patients underwent TAVR at 208 centers with 68 designated as trial centers based on known participation in preapproval clinical trials. Patients receiving TAVR at trial and nontrial hospitals were similar in age and other comorbidities ( Table 1) , with only modest differences observed in the prevalence of chronic heart failure (93% trial hospitals, 89% nontrial hospitals; P<0.01) and peripheral vascular disease (80% trial hospitals, 84% nontrial hospitals; P<0.01). Trial hospitals also had a higher overall surgical aortic valve replacement volume in Medicare beneficiaries than nontrial hospitals (median, 182 versus 140 cases; P<0.001). There was a significantly higher percentage of transapical cases performed at trial hospitals versus nontrial hospitals (23% versus 8%; P<0.01). Patient characteristics at the trial centers were also evaluated before and after FDA approval. There was decreased use of transapical approach (30% versus 19%) and modest decreases in Figure 1 . National transcatheter aortic valve replacement (TAVR) patient volume at trial and nontrial hospitals. Upper, Quarterly volume of patients performed at trial institutions (red) and nontrial institutions (blue). Lower, Quarterly number of centers performing TAVR with new centers (red). Note the number of patients performed at trial centers shows quarterly increases before peaking in the second quarter of 2012. Patient volume at nontrial centers appears to peak at the third quarter of 2012, but the fourth quarter is abbreviated because December was excluded. Hospital Trial Participation and TAVR Outcomes age (84.9 versus 83.2) and congestive heart failure (CHF, 95% versus 93%) after FDA approval, but otherwise there was no differences in multiple attributes over time.
The diffusion of TAVR in 2011 to 2012 is shown in Figure 1 with monotonic quarterly increases both in the number of patients undergoing TAVR and the number of TAVR hospitals. Although there were more patients receiving TAVR at trial hospitals compared with nontrial hospitals in every quarter of 2011 and 2012, the gap progressively narrowed with only a small difference remaining by the end of 2012. The cumulative experience of trial, nontrial, and all TAVR cases, as well as monthly mortality rates, is shown in Figure 2 . The slope of both the trial and the nontrial cases and monthly mortality are relatively constant indicating a relatively constant growth of TAVR in both types of institutions, as well as preserved early survival.
The average number of cases performed during the study period across all centers was 26.7±41.9 (median, 13), with trial hospitals performing an average of 56.1±61.5 (median, 40) TAVRs and nontrial hospitals performing an average of 11.8±9.7 (median, 10) TAVRs. The mean annual rate of TAVR cases per institution, adjusted based on the date of the first TAVR case performed at each institution, was 33.3±32.0 (median, 25) TAVRs per year for trial hospitals and 26.8±34.3 (median, 22) for nontrial hospitals. The rate of TAVR implantation per institution per quarter is shown in Figure 3 . It shows that the rates of TAVR implantation per quarter per institution were relatively stable throughout the period of the study given some quarterly variation. The rate of TAVR cases at nontrial centers progressively increased for the first 3 quarters and then plateaus. Taken together, the patterns of TAVR implantation in Figures 2 and 3 suggest that nontrial centers were an expansion of the TAVR patient population and not a redistribution of cases.
In-hospital, 30-and 90-day outcomes for TAVR patients at trial and nontrial hospitals are listed in Table 2 . TAVR patients at trial hospitals had significantly longer postprocedure length of stay (median of 6 days versus 5 days; P<0.01) and greater postoperative rate of permanent pacemaker implantation rate (10% versus 6%, P<0.01), but there were no differences in unadjusted mortality, rate of stroke, or CHF rehospitalization rates. Kaplan-Meier survival analysis of patients at trial and nontrial hospitals (Figure 4 ) did not demonstrate any statistically significant difference in survival (log-rank P=0.46).
The risk-adjusted logistic regression models for 30-and 180-day mortality are shown in Table 3 . There were no significant differences for trial versus nontrial hospital after adjusting for potential confounders. Older age (>90 years), CHF, transapical approach, chronic kidney disease, and liver disease at 30 days had significantly increased risk-adjusted mortality in the multivariable logistic analysis. At nontrial institutions, there was actually a lower risk adjusted 30-day mortality for an institution's first 10 versus their subsequent experience (odds ratio, 0.63; 95% confidence interval, 0.38-1.02), but this difference did not reach statistical significance. Analysis of the first 20 and first 30 cases versus subsequent cases did not show any significant differences in 30-day or Kaplan-Meier survival analysis. To further analyze the impact of an institution's Institutional transcatheter aortic valve replacement (TAVR) implantation rates by trial status. Note the higher average monthly volume of trial centers throughout the study and the stable quarterly volume at nontrial centers indicating that increased patient volume at nontrial centers was associated with a proportional increase in nontrial centers. Hospital Trial Participation and TAVR Outcomes growing experience and learning curve, the case number of each patient was evaluated in a multivariable model to see if patient n+1 had a decreased 30-day mortality compared with patient n, which was not the case (odds ratio, 1). The number of early deaths in an each institution's experience by case number 1 through 19 and ≥20 cases also showed stable early mortality rates ( Figure 5 ). Annual institutional surgical AVR volume in Medicare patients at nontrial hospitals was also not associated with increased mortality in Kaplan-Meier analysis stratified into terciles (low AVR volume, <74; medium AVR volume, 74-124; and high AVR volume, >124 patients). The CHF rehospitalization rates of TAVR patients at trial and nontrial hospitals were similar at both 30 (10%) and 90 days (18%), and there was no difference between groups.
Discussion
TAVR has undergone rapid adoption among Medicare beneficiaries in the United States. The current study evaluated the initial implementation of TAVR after FDA approval and the CMS National Coverage Determination which set out criteria for TAVR reimbursement. The primary finding is that trial and nontrial hospitals had similar risk-adjusted mortality, periprocedural stroke, and incidence of rehospitalization. Mortality among TAVR patients at nontrial hospitals was similar in the initial cohort of 10 cases when compared with subsequent cases. There was also no association between surgical AVR volume on TAVR outcomes at nontrial hospitals.
Clinical outcomes, particularly in the earliest phase of new technology dissemination, are undoubtedly the result of many factors. TAVR technology dissemination involved new regulatory, proctoring, and multidisciplinary clinical collaboration. The findings of this study show preserved clinical outcomes at nontrial hospitals, a particularly notable finding in the setting of a new and complicated procedure in hospitals without any previous experience. Although occurring in slightly different time periods and not necessarily the same TAVR devices, the outcomes of TAVR introduction in the United States were notably different compared with the initial implementation of TAVR in Europe and other novel cardiovascular technologies in the United States because of the absence of increased mortality associated with an institution's early experience. 1, 13, 14 Among the 2 largest real-world registries in Europe, including the French Aortic National CoreValve and Edwards 2 registry and German Transcatheter Valve Interventions Registry, comprising an overall experience of >3800 patients, the mortality rate was between 9.7% and 12.4% at 30 days. 15, 16 This was conspicuously poorer than similar patients enrolled in the US preapproval studies which had 30-day TAVR mortality rates between 3.4% and 5.0%. 4, 5 In the current study, overall mortality was 5.8% in nontrial hospitals, indicating no decrement during the early phase of TAVR introduction to inexperienced institutions. The diffusion of TAVR in the United States followed a plan of rational dispersion resulting from close collaboration between the major professional societies representing cardiologists and cardiac surgeons, specific mandatory criteria to qualify as a TAVR hospital, and active participation from industry to provide proctoring and education. 17 The CMS approval requirements for TAVR hospitals preselected those with relatively high-volume cardiac catheterization laboratories and cardiac surgery services with significant experience doing advanced procedures on high-risk patients. Specifically, a new TAVR hospital had to perform 1000 cardiac catheterizations with 400 percutaneous coronary interventions annually; have a primary TAVR interventional cardiologist who had performed at least 100 career structural procedures or 30 arterial procedures; an annual institutional surgical AVR volume of at least 50 cases per year; and a TAVR surgeon with at least 100 career standard AVRs. Of these interventional cardiology and surgical cases, 20% had to have been performed in high-risk patients. 9 Device manufacturers of TAVR valves also provided structured proctoring for physicians with a program of simulated procedures, observing TAVR cases, and then at least 2 successful TAVR implantations while being directly supervised by an experienced operator. 5 Details of each potential TAVR recipient were also presented to clinical experts used by the device manufacturer to ensure proper patient selection and to allow for an opportunity for the manufacturer to continually disseminate clinical lessons learned at other hospitals. TAVR hospitals were also required to create of a Heart Team-a collaborative effort between cardiologists and cardiac surgeons to jointly participate in every aspect of each TAVR patient's care from initial evaluation, determination of the best therapeutic approach, presentation of the patient to the device manufacturer clinical consultant(s), and in eligible patients, coparticipation in the TAVR operation. 17 Furthermore, continued certification This program is in marked contrast to the diffusion of many other cardiovascular procedures and technologies, including carotid interventions, endovascular abdominal aortic aneurysm repair, and implantable cardioverter defibrillators, which did not require such rigorous hospital certification based on procedural volume, continued surveillance of clinical performance, the creation of interdisciplinary clinical teams, or mandatory clinical registry surveillance and participation. Some of these elements have been associated with reimbursement for implantable ventricular assist devices and carotid stenting. Registry participation and volume requirements developed iteratively in the postapproval period and were not simultaneously enforced from the point of a program's inception.
The transition from trial to commercial use of TAVR and the effects of the unique policies and clinical environment of commercial TAVR are the focus of this study. The degree to which the patient cohorts were nearly identical between trial and nontrial institutions may have resulted from the rigorous and standardized preoperative review process of each potential TAVR patient by an institutional Heart Team and the device manufacturers. This is different from previous studies and different interventions that have demonstrated different outcomes in nontrial settings compared with clinical trials and dependent on operator volume. 1, 11 Nallamothu et al 11 found that in the dissemination of carotid stent technology, there was 1.9× higher risk of 30-day mortality between low-volume (<6 cases annually) and high-volume operators (≥24 cases annually) and 1.7× higher mortality between patients earlier in an operator experience (1st-11th procedure) compared with later experience (≥12th case). Mallas et al 3 demonstrated that the results of a large, real-world experience of endovascular abdominal aortic aneurysm repair had 6.5× the mortality of contemporary trial results. Alli et al 12 and Cerillo et al 18 have previously described in small single institution studies that ≈30 cases are required to develop the technical skill set to perform TAVR. In the current study, we did not find elevated mortality for the first 10, 20, or 30 cases compared with the subsequent cases or based on institutional volume of surgical AVRs in Medicare patients.
There were a few identifiable differences in clinical outcomes in this study that warrant further investigation. Transapical patients had a worse 30-day and 1-year survival from transfemoral patients. This is consistent with the published clinical trial and US registry experiences and is likely a consequence of elevated risk factor profile in this group of patients with severe peripheral vascular disease. 4, 5, 19 The comorbidities of chronic kidney disease and CHF were both significantly associated with 30-and 180-day mortality. Patients with chronic kidney disease are particularly a important subgroup of patients that were excluded from the preapproval TAVR clinical trials, so the results of TAVR in this patient population were previously unknown. There were also several other comorbidities associated with 180-day mortality, including chronic obstructive pulmonary disease, that may represent cohorts of patients with elevated risk of mortality.
This study has important limitations, including those inherent to a retrospective analysis of Medicare data, which do not include detailed clinical information (eg, left ventricular ejection fraction, valve type, valve size, STS score) that may have confounded the comparisons. Despite this, the patients in the current study had similar age, incidence of congestive heart failure, and stroke and mortality outcomes when compared with the TVT registry, the CMS mandated clinical registry of TAVR procedures and outcomes. 19 The fee-for-service Medicare patient population in the current study differs somewhat from the TVT registry in that patients enrolled in ongoing clinical trials in the postapproval era are captured in the current data set. This data however does not include patients who are not fee-for-service Medicare patients, who are captured in the TVT registry. Furthermore, administrative databases and retrospective analyses have limited ability to fully explain the exact reasons for the preserved outcomes in nontrial hospitals regardless of TAVR experience and surgical AVR volume in comparison with more experience and higher volume trial hospitals. Because the Current Procedural Terminology codes for TAVR were not created until 2011, the outcomes of TAVR patients in Medicare before 2011 could not be evaluated using Medicare data alone. It is possible that some occurrences of TAVR or subsequent major clinical events were miscoded and thus omitted from our analysis; however, this was likely to be rare because both TAVR and major clinical events generate high-cost hospitalizations that would likely produce Medicare claims for payment.
Conclusions
Our study finds that centers with and without previous TAVR trial experience had similar stroke, readmission, and mortality outcomes. This is an important finding because TAVR was the first cardiovascular technology in the United States with mandated requirements for hospital eligibility, continued surveillance of clinical outcomes, and interprofessional collaboration.
